Viridian Therapeutics, Inc./DE (VRDN)

Every figure this model derived for VRDN, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 1,696,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 981,530,000 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents 2026-06-30
current assets 1,081,270,000 AssetsCurrent 2026-06-30
current liabilities 63,794,000 LiabilitiesCurrent 2026-06-30
equity 662,097,000 StockholdersEquity 2026-06-30
interest expense 15,611,000 InterestExpenseNonoperating 2026-06-30
ocf -333,343,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 71,127,000 RevenueFromContractWithCustomerIncludingAssessedTax 2026-06-30
sbc 53,613,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up VRDN on one particular measure came for.

RatioValue
cash operating margin-493.65
current ratio17.0
current ratio reported16.95
deferred revenue growth-37.15
fcf margin-471.04
growth cv1.99
interest cover-25.96
operating margin-569.68
owner earnings margin-546.42
revenue growth23220.33
revenue growth per share23220.33
rule of 4022650.64
sbc pct revenue75.38

What to be careful about

What this model itself distrusts about VRDN's figures. Written by the derivation as it ran, not added afterwards.